Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.